Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
DNLI 
Denali Therapeutics Inc (DNLI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: DNLI (1-star) is a SELL. SELL since 2 days. Simulated Profits (-14.40%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
19 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $31.5
1 Year Target Price $31.5
| 15 | Strong Buy |
| 4 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.56% | Avg. Invested days 31 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.94B USD | Price to earnings Ratio - | 1Y Target Price 31.5 |
Price to earnings Ratio - | 1Y Target Price 31.5 | ||
Volume (30-day avg) 19 | Beta 1.23 | 52 Weeks Range 10.57 - 33.33 | Updated Date 09/16/2025 |
52 Weeks Range 10.57 - 33.33 | Updated Date 09/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.81 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -24.99% | Return on Equity (TTM) -39.69% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 1071759578 | Price to Sales(TTM) 3643.65 |
Enterprise Value 1071759578 | Price to Sales(TTM) 3643.65 | ||
Enterprise Value to Revenue 2843.16 | Enterprise Value to EBITDA -8.66 | Shares Outstanding 146212000 | Shares Floating 131975588 |
Shares Outstanding 146212000 | Shares Floating 131975588 | ||
Percent Insiders 9.83 | Percent Institutions 96.25 |
Upturn AI SWOT
Denali Therapeutics Inc
Company Overview
History and Background
Denali Therapeutics Inc. was founded in 2015 and is focused on developing therapies for neurodegenerative diseases. It went public in 2017. Significant milestones include establishing partnerships with major pharmaceutical companies and advancing its pipeline of therapeutic candidates through clinical trials.
Core Business Areas
- Neurodegenerative Disease Therapies: Denali focuses on developing therapies for diseases like Alzheimer's, Parkinson's, ALS, and frontotemporal dementia. They are focused on treatments that can cross the blood-brain barrier.
Leadership and Structure
Denali is led by CEO Ryan Watts. The organizational structure includes research and development, clinical operations, and corporate functions. The Board of Directors includes prominent figures in the biotechnology industry.
Top Products and Market Share
Key Offerings
- SAR443820/DNL310 (Hunter Syndrome): SAR443820/DNL310 is designed to treat Hunter syndrome. It is partnered with Sanofi. Market share data is not publicly available. Competitors: BioMarin Pharmaceutical (Vimizim).
- DNL151 (Parkinson's Disease): DNL151 is a LRRK2 inhibitor for Parkinson's disease. Market share data is not publicly available as it is still in development. Competitors: Biogen, Roche, and other companies developing Parkinson's disease therapies.
Market Dynamics
Industry Overview
The neurodegenerative disease market is large and growing due to aging populations. There is a high unmet need for effective therapies.
Positioning
Denali is positioned as a leader in developing therapies that can cross the blood-brain barrier. Their focus on this technological aspect provides a competitive advantage.
Total Addressable Market (TAM)
The TAM for neurodegenerative diseases is estimated to be in the tens of billions of dollars annually. Denali is positioned to capture a significant share of this market with successful therapies.
Upturn SWOT Analysis
Strengths
- Novel blood-brain barrier technology
- Strong partnerships with large pharmaceutical companies
- Experienced management team
- Deep pipeline of therapeutic candidates
Weaknesses
- High cash burn rate
- Reliance on clinical trial success
- Limited number of approved products
- Dependence on Partnerships
Opportunities
- Expanding pipeline into new neurodegenerative diseases
- Securing regulatory approvals for lead candidates
- Expanding partnerships with other pharmaceutical companies
- Advancements in blood-brain barrier technology
Threats
- Clinical trial failures
- Competition from other biotechnology and pharmaceutical companies
- Regulatory hurdles
- Patent challenges
Competitors and Market Share
Key Competitors
- BIIB
- ROCHE.SW
- ABBV
Competitive Landscape
Denali's competitive advantage lies in its blood-brain barrier technology. However, it faces competition from larger, more established pharmaceutical companies with broader product portfolios.
Growth Trajectory and Initiatives
Historical Growth: Denali's historical growth has been driven by progress in its clinical pipeline and establishment of key partnerships.
Future Projections: Analyst projections vary, but generally anticipate revenue growth driven by potential regulatory approvals and expanded partnerships.
Recent Initiatives: Recent initiatives include advancing its lead programs through clinical trials and expanding its research and development efforts into new areas of neurodegenerative disease.
Summary
Denali Therapeutics is a biotechnology company with potential driven by its innovative blood-brain barrier technology and partnerships. It faces challenges related to clinical trial success and financial sustainability. A key strength lies in its novel technology, while a weakness is its high cash burn rate. Investors should monitor clinical trial outcomes and partnership developments.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings (10-K, 10-Q), Company Website, Investor Presentations, Analyst Reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. Market share data is an estimate and may vary. Actual results may differ materially from projections.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Denali Therapeutics Inc
Exchange NASDAQ | Headquaters South San Francisco, CA, United States | ||
IPO Launch date 2017-12-08 | Co-Founder, President, CEO & Director Dr. Ryan J. Watts Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 486 | |
Full time employees 486 | |||
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.